Neuberger Berman Group LLC Cuts Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Neuberger Berman Group LLC trimmed its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 15.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,094,421 shares of the medical device company's stock after selling 194,321 shares during the quarter. Neuberger Berman Group LLC owned 0.28% of DexCom worth $85,112,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Versant Capital Management Inc bought a new position in DexCom in the fourth quarter valued at about $25,000. Private Trust Co. NA increased its position in shares of DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after purchasing an additional 245 shares during the last quarter. TD Private Client Wealth LLC lifted its stake in shares of DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after purchasing an additional 167 shares during the period. Larson Financial Group LLC boosted its holdings in shares of DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after buying an additional 137 shares during the last quarter. Finally, Heck Capital Advisors LLC bought a new stake in DexCom during the fourth quarter valued at approximately $38,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Trading Up 1.8 %

DXCM traded up $1.19 during trading on Tuesday, reaching $68.58. The company had a trading volume of 1,795,768 shares, compared to its average volume of 4,184,235. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The business has a 50 day simple moving average of $76.49 and a 200-day simple moving average of $76.68. The stock has a market cap of $26.89 billion, a P/E ratio of 47.96, a PEG ratio of 2.30 and a beta of 1.50. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $139.24.

Remove Ads

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Wall Street Analyst Weigh In

DXCM has been the topic of several recent research reports. Canaccord Genuity Group increased their price target on shares of DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a research report on Friday, February 14th. Morgan Stanley lifted their target price on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Baird R W upgraded DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Citigroup raised their price objective on DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research note on Tuesday, March 4th. Finally, Mizuho assumed coverage on DexCom in a research note on Thursday, April 10th. They set an "outperform" rating and a $85.00 price objective for the company. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, DexCom presently has a consensus rating of "Moderate Buy" and an average target price of $99.00.

Insider Buying and Selling

In other DexCom news, COO Jacob Steven Leach sold 14,076 shares of the company's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $990,668.88. Following the completion of the sale, the chief operating officer now directly owns 313,497 shares in the company, valued at approximately $22,063,918.86. This represents a 4.30 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael Jon Brown sold 13,000 shares of the firm's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $914,940.00. Following the transaction, the executive vice president now owns 105,602 shares in the company, valued at approximately $7,432,268.76. This represents a 10.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 105,009 shares of company stock valued at $8,044,178 in the last 90 days. Company insiders own 0.30% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.